Form 4: ImmunityBio CEO Richard Adcock Acquires Stock Options and Restricted Stock Units

Richard Adcock, CEO and President of ImmunityBio, acquired stock options and restricted stock units (RSUs) on February 10, 2025, according to a recent SEC filing.

Summary

• Richard Adcock, CEO and President of ImmunityBio, filed a Form 4 with the SEC.
• The filing reports the acquisition of derivative securities and non-derivative securities.
• On February 10, 2025, Adcock acquired 822,368 Restricted Stock Units (RSUs) and 2,812,500 stock options.
• The RSUs and stock options vest in equal annual installments over three years, starting on February 10, 2025, contingent upon continued service.
• The exercise price for the stock options is $3.39.
• The RSUs represent a contingent right to receive one share of ImmunityBio common stock each.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and suggests confidence in the CEO's leadership and the company's future prospects. However, the value is contingent on future performance.

Positives

• The acquisition of RSUs and stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CEO.

Risks

• The value of the RSUs and stock options is dependent on the future performance of ImmunityBio's stock price.
• If Adcock ceases to be a Service Provider, the unvested RSUs and stock options will be forfeited.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of the RSUs and stock options is tied to the CEO's continued service, suggesting an expectation of his continued leadership.

Industry Context

Stock option and RSU grants are a common practice in the biotechnology industry to incentivize and retain key executives. The size and vesting schedule of these grants are typical for a company of ImmunityBio's size and stage of development.

Comparison to Industry Standards

• Comparing ImmunityBio's executive compensation structure to companies like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals reveals that stock options and RSUs are standard components of executive pay packages.
• The vesting schedules are also in line with industry norms, typically ranging from three to five years.
• The specific value of the grants would need to be compared to companies of similar market capitalization and revenue to determine if they are above or below average.

Stakeholder Impact

• Shareholders may view the grant of RSUs and stock options positively, as it aligns the CEO's interests with theirs.
• Employees may be motivated by the CEO's commitment to the company.

Key Dates

Keywords

ImmunityBio, IBRX, Richard Adcock, SEC Form 4, Restricted Stock Units, Stock Options, Beneficial Ownership, Executive Compensation